Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

letter

. 2024 Jan 18;14(1):e1552. doi: 10.1002/ctm2.1552

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2024 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.

This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Comparison of gene mutation patterns, sensitivity to immunotherapy and chemotherapy and published molecular classifications. (A) The top six most differently mutated genes between rich‐Treg PCa (TregR) and poor‐Treg PCa (TregP), including TP53, MUC17, NALCN, DCHS2, DCHS2, MXRA5 and PIK3CA. (B) SubMap analysis for deciphering the different responses to anti‐PD‐1 or CTLA‐4 therapy. (C) Comparison of the sensitivity to eight chemotherapeutic drugs, including bicalutamide, doxorubicin, etoposide, gemcitabine, mitomycin C, vinorelbine, cisplatin, 5‐fluorouracil and the lower IC50, the higher the sensitivity. (D) Sankey plot showed the distributions of TregP and TregR in PMOC classification (left) and PAM50 classification (right). (E) χ2 test table showed the concrete proportions of TregP and TregR subtypes in different molecular classifications.